Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators. Xu J, et al. Among authors: mao y. JAMA. 2023 Dec 5;330(21):2064-2074. doi: 10.1001/jama.2023.19918. JAMA. 2023. PMID: 38051328 Clinical Trial.
The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study.
Feng W, Wang Y, Ran F, Mao Y, Zhang H, Wang Q, Lin W, Wang Z, Hu J, Liao W, Zhang T, Chu Q, Xiong W, Yi T, Yi J, Ma S, Sun Y, Meng L, Liu C, Zhou S, Zheng D, Wang S, Lin H, Fang W, Li J, Wu M. Feng W, et al. Among authors: mao y. Front Med (Lausanne). 2022 Oct 4;9:918468. doi: 10.3389/fmed.2022.918468. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36267618 Free PMC article.
A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non-small-cell lung cancer who have progressed after anti-PD-1/L1 therapy.
Zhao Y, Chen X, Yao J, Long J, Mao Y, Wu D, Zang A, Zhao J, Liu Z, Meng R, Chen Y, Luo Y, Guo Q, Li L, Cui J. Zhao Y, et al. Among authors: mao y. Cancer Med. 2024 Feb;13(3):e6855. doi: 10.1002/cam4.6855. Epub 2024 Jan 12. Cancer Med. 2024. PMID: 38214075 Free PMC article. Clinical Trial.
[Research advances on severe burn infection and cytokine storm].
Chen ZY, Hu SQ, Liu DW, Zhang HY, Guo GH, Mao YG. Chen ZY, et al. Among authors: mao yg. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023 Apr 20;39(4):391-395. doi: 10.3760/cma.j.cn501225-20220412-00134. Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023. PMID: 37805745 Review. Chinese.
Comprehensive molecular characterization of long-term glioblastoma survivors.
Xu H, Chen X, Sun Y, Hu X, Zhang X, Wang Y, Tang Q, Zhu Q, Song K, Chen H, Sheng X, Yao Y, Zhuang D, Chen L, Mao Y, Qin Z. Xu H, et al. Among authors: mao y. Cancer Lett. 2024 May 9:216938. doi: 10.1016/j.canlet.2024.216938. Online ahead of print. Cancer Lett. 2024. PMID: 38734160
9,740 results